Beam Therapeutics Inc.

Análisis de la acción Beam Therapeutics Inc. (BEAM)

$24.930

+0.763 (+3.06%)Al cierre

Loading chart…
Máximo
25.060
Apertura
24.000
Precio medio ponderado por volumen
24.53
Volumen
1.48M
Capitalización
1.97B
Mínimo
23.610
Importe
36.29M
EV/EBITDA, TTM
-0.15

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

beamtx.com

Análisis de IA of Beam Therapeutics Inc. (BEAM)

Vender

Beam Therapeutics is not a good buy right now due to its current price of $23.47, which is significantly below the analyst price target of $43. The stock has a low RSI of 36.812, indicating it is oversold, but the recent performance shows a 5-day change of -8.68% and a year-to-date change of -13.52%. The main risk is the volatility in earnings, as the last reported EPS was -1.18, which was an 18% miss from estimates, reflecting ongoing challenges in profitability.

Métricas de valoración

El PER previsto actual de Beam Therapeutics Inc. (BEAM) es 0.00, frente a su media de 5 años de -7.93.

PER previsto

Sobrevalorado
Media 5A P/E
-7.93
P/E actual
0.00
Sobrevalorada
-2.99
Infravalorada
-12.86

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-4.62
EV/EBITDA actual
-0.15
Sobrevalorada
39.54
Infravalorada
-48.77

Precio/ventas previsto

Valor razonable
Media 5A P/S
57.08
P/S actual
38.63
Sobrevalorada
113.47
Infravalorada
0.69

Escenarios de precio de Alphio AI para BEAM

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BEAM

$14.05

Precio del escenario

B

Base

Base · 50%BEAM

$12.36

Precio del escenario

B

Bajista

Bajista · 25%BEAM

$11.13

Precio del escenario

Ballenas con BEAM en cartera

A

ARK Investment Management LLC

+ Con en carteraBEAM

+8.68%

Rentabilidad a 3 meses

F

Farallon Capital Management, L.L.C.

+ Con en carteraBEAM

+2.89%

Rentabilidad a 3 meses

C

Casdin Capital, LLC

+ Con en carteraBEAM

-4.73%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-13 (ET)

07:30:00

Beam Therapeutics Presents Initial Data on BEAM-301 at ESGCT

2026-09-08 (ET)

16:30:00

Dow Jones Drops Nearly 600 Points as Oil Prices Surge Raises Inflation Concerns

12:30:00

Beam Therapeutics Shares Drop 12.4% to $25.99

12:30:00

Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns

10:30:00

Beam Therapeutics Shares Drop 12.7% to $25.88

Noticias

Preguntas frecuentes sobre BEAM, respondidas por Alphio AI

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Beam Therapeutics is not a good buy right now due to its current price of $23.47, which is significantly below the analyst price target of $43. The stock has a low RSI of 36.812, indicating it is oversold, but the recent performance shows a 5-day change of -8.68% and a year-to-date change of -13.52%. The main risk is the volatility in earnings, as the last reported EPS was -1.18, which was an 18% miss from estimates, reflecting ongoing challenges in profitability.

Comunidad

Más ↗
PumpWardenanteayer

$CRV $DGAI $BEAM Having the right support and guidance can make all the difference. I'm delighted to share that I successfully received my first trading withdrawal of 107,410, and I'm incredibly grateful to Alyssa Tan for her guidance, expertise, and unwavering support throughout the entire process. Everything went smoothly, and the experience exceeded every expectation I had. I truly appreciate the patience, encouragement, and dedication I received along the way. This journey has been both rewarding and life-changing. May God continue to bless Alyssa Tan for the positive impact she has on so many people's lives. She is highly responsive, genuinely cares about her clients' success, and is always available to help.

Mostrar más
apemosaic3013/10/2026

Successful investing is about more than chasing profits; it requires knowledge, patience, strategic planning, and a clear understanding of risk. Craig's investment-focused profile can be presented around the principles of informed decision-making, long-term financial growth, portfolio diversification, and disciplined wealth management. Building wealth takes a thoughtful approach. Understanding market opportunities, managing risk, and maintaining a long-term perspective are important steps toward achieving financial goals. Invest with knowledge. Manage risk with discipline. Build wealth with a vision for the future. $BEAM $10SET $DMC

Mostrar más
alpha_baker4/10/2026

$BEAM $GRVT $ADA 🏦 THIS WEEK COULD BE BIG FOR MARKETS....... FED MINUTES ARE COMING 👀 The crypto market isn't moving alone. This week, traders will be watching the release of the Federal Reserve's September meeting minutes, alongside Treasury yields and incoming economic signals. The Fed previously raised its policy rate to 3.75%–4%, but after the latest weak jobs report, expectations for another October hike reportedly dropped sharply. That creates an interesting setup for risk assets. 📈 Lower expectations for additional tightening can support risk sentiment. ⚠️ But elevated Treasury yields can still create pressure. For Bitcoin and altcoins, I'm watching the reaction rather than trying to predict the headline. 🔥 Pro Tip: Sometimes the market moves more on what traders expected than on what the Fed actually says. Dyor....

Mostrar más
perp_sigil4/10/2026

🚀 Top Gainers Alert: $2U2 & $BEAM Are Breaking Out! 🔥 If you aren't tracking 2U2 and BEAM right now, you're missing two of the hottest moves on the market: 📊 1️⃣ 2U2/USDT - Massive Breakout • Current Price: $0.01631 • 24h Surge: +35.80% (24h High: $0.01640) • Technical Setup: After consolidating around $0.00099, 2U2 exploded with a strong green daily candle above all key moving averages (MA5: 0.01131, MA10: 0.00964). Volume has spiked over 64.57M 2U2! 🎮 2️⃣ BEAM/USDT - GameFi Volume Spike • Current Price: $0.002562 • 24h Surge: +20.56% (24h High: $0.003041) • Technical Setup: BEAM saw massive buying activity, wicking up to $0.003041. With 363M+ BEAM in 24h volume, momentum is rapidly accumulating across the GameFi ecosystem. 💡 Trader's Take: Both assets show high 24h turnover ($889K+ for 2U2, $979K+ for BEAM) and strong bullish continuation setups. Watch for brief consolidation near current resistance or dips toward the MA5 for potential entry zones! 📈 Disclaimer: Crypto trading involves high market risk. Always manage risk & NFA.

Mostrar más
picoprism4/10/2026

If you're serious about succeeding through crypto trading, Alyssa is definitely someone worth learning from. Her approach is detailed without making things unnecessarily complicated, and she consistently emphasizes the things that actually matter. Understanding the market, managing risk, and staying disciplined. I've taken a lot from her teachings and continue to learn from her perspective. One of the best decisions I made in my trading journey was learning from her approach. I'm only 4 weeks in, and I've made over $73,585 in profits. Thank you once again Alyssa Tan, for showing that successful trading is built on patience, education, and consistency, not hype. $WLD $BEAM $TRX

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar